Published in Cancer Law Weekly, August 12th, 2006
"In this review, we discuss the recent identification of ARF-BPI (also known as Mule, UREBI, E3 (histone), LASUI, and HectH9). ARF-BPI, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53," researchers in the United States reported.
"Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BPI stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BPI also caused cell growth repression in p53-null cells and breast cancer cells with mutant p53," explained D. Chen and colleagues, Columbia University.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.